Sclerosing Cholangitis

IWBCA
Feb 19
13 min read

Sclerosing cholangitis is a chronic, progressive disease of the bile ducts characterized by inflammation, scarring, and narrowing of the intrahepatic and extrahepatic biliary tree, which can eventually lead to cholestasis, cirrhosis, portal hypertension, and an elevated risk of hepatobiliary and colorectal cancers, particularly in people with coexisting inflammatory bowel disease.

Overview

What is sclerosing cholangitis?

Sclerosing cholangitis is uncommon in the general population, but for the it affects, the stakes are extraordinarily high. Among individuals who have both primary sclerosing cholangitis (PSC) and inflammatory bowel disease, the lifetime risk of bile duct cancer (cholangiocarcinoma) may reach 10 to 15 percent, which is dramatically higher than in the general population. Up to half of patients are asymptomatic at the time of diagnosis and come to attention only because of abnormal liver tests, yet some of these “well-feeling” individuals already have advanced scarring and a significantly increased risk of hepatobiliary and colorectal cancers that require close surveillance. For those who progress to advanced liver disease, liver transplantation becomes a key option, and five-year survival after transplant often exceeds 80 to 85 percent in large series, allowing many people to return to active, high-functioning lives.

Sclerosing cholangitis describes a group of conditions in which the bile ducts become inflamed, fibrotic, and narrowed over time. The most common form is primary sclerosing cholangitis, in which the cause is not fully understood. PSC typically affects both the large intrahepatic and extrahepatic bile ducts, producing multifocal strictures and segmental dilatations that can create a “beaded” appearance on imaging. Secondary sclerosing cholangitis refers to similar ductal changes arising from identifiable causes, such as ischemia, prior biliary surgery or injury, recurrent infections, or immune-mediated diseases distinct from PSC.

In PSC, the chronic injury and scarring of the bile ducts impair bile flow from the liver to the intestine. This cholestasis damages hepatocytes, promotes fibrosis, and can ultimately result in cirrhosis and liver failure if the process continues unchecked. PSC often coexists with inflammatory bowel disease, especially ulcerative colitis, and this gut–liver link shapes both clinical presentation and long-term surveillance strategies, particularly around cancer risk. There is currently no approved medical therapy that reliably halts or reverses PSC progression, and liver transplantation remains the only established curative option for advanced disease, with outcomes that are generally favorable when referral and evaluation occur in a timely manner.

Symptoms

What are the most common symptoms associated with sclerosing cholangitis?

Many people with PSC are asymptomatic at the time of diagnosis, which is often made when liver tests are incidentally abnormal. As the disease progresses, symptoms reflect cholestasis, episodic biliary obstruction, and evolving liver dysfunction.

Asymptomatic Elevation of Liver Tests: A large proportion of individuals are diagnosed after routine blood work reveals persistently elevated cholestatic enzymes, particularly alkaline phosphatase and gamma-glutamyl transferase. At this stage, people may feel entirely well and have no specific liver symptoms.
Fatigue and Reduced Stamina: Persistent tiredness and reduced capacity for daily activities are common and can occur even when other symptoms are relatively mild. Fatigue in PSC often has multiple contributors, including cholestasis, systemic inflammation, sleep disruption, and coexisting inflammatory bowel disease.
Pruritus (Itching): Generalized itching, often worse at night and affecting the limbs, trunk, or scalp, is a hallmark symptom of cholestatic liver disease. It can be severe enough to disturb sleep, impair concentration, and cause excoriations and skin breakdown from scratching.
Right Upper Quadrant Discomfort: Some people develop a dull ache or a sense of fullness under the right rib cage, reflecting hepatomegaly or biliary distension. This discomfort is usually intermittent and may be provoked by episodes of biliary obstruction.
Jaundice and Dark Urine: As cholestasis worsens, bile pigments accumulate in the blood, causing yellowing of the skin and sclera. Urine may appear dark, and stools can become pale or clay colored. Jaundice may appear gradually with progressive disease or acutely during episodes of cholangitis or high-grade biliary obstruction.
Recurrent Episodes of Cholangitis: People with strictures of the bile ducts are at risk for bacterial cholangitis. Typical features include fever, chills, right upper quadrant pain, and jaundice. These episodes can present abruptly, require urgent antibiotic therapy, and may necessitate endoscopic decompression.
Features of Advanced Liver Disease: In later stages, signs of cirrhosis and portal hypertension can emerge, including ascites, peripheral edema, easy bruising, gastrointestinal bleeding from varices, and muscle wasting. Cognitive changes such as confusion or sleep–wake reversal may signal hepatic encephalopathy.
Extrahepatic and Associated Symptoms: Because PSC commonly coexists with inflammatory bowel disease, many individuals also report diarrhea, rectal bleeding, abdominal cramping, or urgency related to colitis. Arthralgias, skin conditions, and fatigue related to systemic immune activation may also be present.

Causes

What causes sclerosing cholangitis?

The causes of sclerosing cholangitis differ between primary and secondary forms. In PSC, the etiology appears multifactorial, involving genetic susceptibility, immune dysregulation, and gut–liver interactions. In secondary sclerosing cholangitis, a specific injuring event or condition can typically be identified.

Primary Sclerosing Cholangitis (PSC): In PSC, chronic inflammation and fibrosis develop without a clear precipitating insult. Genetic studies indicate that certain HLA and non-HLA variants increase susceptibility, particularly in individuals of Northern European ancestry. Many people with PSC also have inflammatory bowel disease, especially ulcerative colitis, and accumulating evidence supports an immune-mediated process in which gut-derived antigens and an altered intestinal microbiome contribute to ongoing biliary injury.
Secondary Sclerosing Cholangitis: Secondary forms arise when bile ducts are damaged by known processes. Causes include prolonged bile duct obstruction, ischemic injury after vascular compromise or shock, strictures or leaks following biliary surgery or transplantation, recurrent bacterial cholangitis, and certain infections or toxic exposures. In these settings, treating or removing the underlying cause is central to halting progression.
Immune Dysregulation and Autoimmunity: PSC shares features with autoimmune liver disease but does not fit classic autoimmune hepatitis. Adaptive and innate immune responses directed against cholangiocytes, along with abnormal homing of gut-primed lymphocytes to the liver, appear to drive chronic inflammation. Some individuals have overlap syndromes with autoimmune hepatitis, which can influence treatment choices.
Gut–Liver and Microbiome Factors: The strong association between PSC and inflammatory bowel disease suggests a bidirectional gut–liver axis. Microbial products, bile acids, and inflammatory mediators from the intestine reach the liver via the portal circulation. Changes in gut microbiota composition and barrier function may increase cholangiocyte exposure to injurious signals, contributing to progressive ductal scarring.
Genetic and Environmental Interactions: PSC clusters within families, and first-degree relatives of affected individuals have higher rates of PSC and related immune-mediated conditions than the general population. Environmental modifiers, including infections, medications, and possibly diet or toxin exposures, are thought to interact with genetic risk but have not been fully delineated.

Risk Factors

Who is at higher risk of developing sclerosing cholangitis?

PSC is a rare disease, but certain characteristics and coexisting conditions increase the likelihood of its development. Risk factors for secondary sclerosing cholangitis differ and are tied to specific biliary or vascular events.

Inflammatory Bowel Disease: Inflammatory bowel disease, particularly ulcerative colitis, is the strongest clinical association with PSC. A substantial proportion of individuals with PSC have concurrent colitis, often with distinct features such as right-sided predominance and rectal sparing. Conversely, a smaller percentage of people with ulcerative colitis develop PSC, but this subgroup carries unique hepatobiliary and colorectal cancer risks.
Age and Sex: PSC is most often diagnosed in young to middle-aged adults, with a peak in the third and fourth decades, although pediatric and later-onset cases occur. Many cohorts show a predominance of individuals assigned male at birth, particularly in Western populations.
Genetic Predisposition: Familial clustering and shared HLA haplotypes support a heritable component of PSC risk. First-degree relatives of affected individuals may have a higher incidence of PSC, autoimmune liver disease, or inflammatory bowel disease compared with unrelated controls, although the absolute risk for any given relative remains low.
Geography and Ancestry: PSC is reported more frequently in Northern Europe, North America, and Australia, with lower but rising recognition in Asia and other regions. These patterns likely reflect a combination of genetic background, environmental exposures, and diagnostic awareness.
Conditions Predisposing to Secondary Sclerosing Cholangitis: Secondary sclerosing cholangitis is more likely in people who have experienced prolonged biliary obstruction, complex biliary surgery or transplant-related complications, severe critical illness with ischemic injury to the biliary tree, or recurrent episodes of bacterial cholangitis. Certain infections and infiltrative disorders can also produce secondary stricturing of bile ducts.

Complications

What complications can sclerosing cholangitis cause?

PSC and secondary sclerosing cholangitis can lead to a wide range of hepatic and extrahepatic complications. Some complications relate to progressive liver disease, whereas others arise from chronic inflammation and structural changes in the biliary tree.

Progressive Cholestasis, Fibrosis, and Cirrhosis: Ongoing bile duct injury and obstruction cause chronic cholestasis, which damages hepatocytes and stimulates fibrogenesis. Over time, this process can culminate in bridging fibrosis and cirrhosis, with associated portal hypertension, hepatic synthetic dysfunction, and increased vulnerability to infections and acute decompensation.
Portal Hypertension and Its Sequelae: As intrahepatic resistance rises, portal pressure increases, leading to splenomegaly, thrombocytopenia, ascites, varices, and an increased risk of variceal hemorrhage. These complications often define the need for closer monitoring and consideration of liver transplantation.
Recurrent Bacterial Cholangitis: Multifocal strictures impede bile flow and favor bacterial overgrowth within the biliary tree. Recurrent cholangitis episodes can require repeated hospitalizations, intravenous antibiotics, and endoscopic interventions, and they accelerate the deterioration of liver function.
Cholangiocarcinoma and Hepatobiliary Malignancies: PSC confers a marked increase in risk of cholangiocarcinoma, which is a leading cause of death in this population. Estimates suggest that a significant minority of individuals with PSC will develop cholangiocarcinoma over their lifetime, with a yearly incidence substantially higher than that of the general population. Gallbladder carcinoma and, in cirrhotic patients, hepatocellular carcinoma also occur at elevated rates, necessitating structured surveillance in at-risk groups.
Colorectal Neoplasia in PSC–IBD: People with PSC and coexisting inflammatory bowel disease, especially ulcerative colitis, have a higher risk of colorectal dysplasia and cancer compared with individuals who have colitis alone. This risk appears to begin early in the disease course and persists after liver transplantation, which is why enhanced colonoscopic surveillance strategies are recommended for this subgroup.
Metabolic and Nutritional Consequences: Chronic cholestasis can impair the absorption of fat-soluble vitamins and lipids, leading to deficiencies in vitamins A, D, E, and K, osteopenia or osteoporosis, coagulopathy, and night vision difficulties. Weight loss, sarcopenia, and frailty may develop as chronic liver disease advances.
Post-Transplant Complications and Disease Recurrence: Liver transplantation improves survival for advanced PSC but introduces risks such as rejection, vascular and biliary complications, infection, and medication side effects. PSC can recur in the transplanted liver in a subset of patients, necessitating ongoing long-term follow-up.

Diagnosis and Testing

How is sclerosing cholangitis diagnosed?

Diagnosis relies on a combination of biochemical, imaging, histologic, and clinical findings. The primary goals are to document characteristic bile duct changes, assess liver involvement, and exclude alternative explanations for cholangiopathy.

Clinical Evaluation and Laboratory Tests: Initial evaluation includes a detailed history focusing on pruritus, jaundice, prior biliary interventions, episodes of cholangitis, inflammatory bowel disease, and family history. Physical examination looks for jaundice, hepatosplenomegaly, and signs of chronic liver disease. Blood tests typically show a cholestatic pattern with elevated alkaline phosphatase and gamma-glutamyltransferase, variably elevated bilirubin, and sometimes elevated transaminases. Testing for viral hepatitis, autoimmune liver disease, and metabolic liver disorders helps exclude other causes.
Magnetic Resonance Cholangiopancreatography (MRCP): MRCP is the preferred noninvasive imaging modality for PSC. It visualizes the biliary tree and can reveal multifocal strictures and intervening dilatations in intrahepatic and extrahepatic ducts, producing a characteristic beaded or pruned appearance. MRCP also helps distinguish large-duct PSC from other biliary disorders and guides further evaluation.
Endoscopic Retrograde Cholangiopancreatography (ERCP): ERCP is now used primarily for therapeutic purposes and targeted sampling rather than for initial diagnosis in most cases. It allows direct visualization of strictures, brush cytology, biopsy of dominant or suspicious lesions, and, in selected patients, interventions such as balloon dilatation or stent placement. ERCP carries procedure-related risks and is reserved for situations in which the benefits outweigh those risks.
Liver Biopsy: Histologic evaluation can be helpful when imaging is normal or equivocal, especially in suspected small-duct PSC, overlap syndromes with autoimmune hepatitis, or other complex scenarios. Biopsy may show periductal “onion skin” fibrosis, ductopenia, and features of chronic cholestatic injury, although these classic findings are not always present.
Assessment for Associated Conditions: People diagnosed with PSC are typically evaluated for inflammatory bowel disease with colonoscopy and biopsies, even if they have minimal gastrointestinal symptoms, because subclinical disease is common. Screening for other immune-mediated conditions and for complications such as portal hypertension, metabolic bone disease, and vitamin deficiencies is also important at baseline and during follow-up.
Classification of Extent and Severity: Clinicians consider the distribution of duct involvement, presence of small-duct versus large-duct disease, biochemical severity, and evidence of cirrhosis or portal hypertension. Prognostic models that incorporate laboratory values, imaging features, and clinical parameters can help estimate disease trajectory and inform the timing of transplant evaluation.

Management and Treatment

How is sclerosing cholangitis treated and monitored?

Management combines supportive care, targeted treatment of complications, and careful surveillance for malignancy and progression of liver disease. For PSC, no medical therapy has been definitively proven to halt disease progression, and liver transplantation remains the only established curative option for advanced stages.

Risk Factor Modification and Supportive Measures: General liver health measures include avoiding hepatotoxic medications and alcohol, vaccination against hepatitis viruses and other preventable infections, and maintaining adequate nutrition. Pruritus can be treated with bile acid sequestrants, rifampin, opioid antagonists, or other agents in a stepwise fashion. Fat-soluble vitamin supplementation and bone health optimization are important components of long-term care.

Biliary Interventions for Dominant Strictures: When imaging or symptoms suggest a high-grade or dominant stricture, endoscopic evaluation with ERCP may be indicated. Balloon dilatation, with or without temporary stenting, can relieve obstruction, reduce cholangitis episodes, and improve cholestasis in selected patients. Any new or worsening stricture requires careful assessment for cholangiocarcinoma with imaging and cytologic or histologic sampling.

Medical Therapy and Clinical Trials in PSC: Ursodeoxycholic acid is often used in cholestatic liver diseases and can improve biochemical markers in PSC, but its impact on long-term clinical outcomes remains uncertain. Current guidance supports considering moderate doses in selected patients if there is a meaningful biochemical and symptomatic response, while recognizing that routine high-dose therapy is not recommended. Newer agents targeting bile acid pathways, fibrosis, and immune signaling are under active investigation, and enrollment in clinical trials is encouraged when available.

Treatment of Overlap and Secondary Conditions: Overlap syndromes with autoimmune hepatitis may respond to immunosuppressive regimens that include corticosteroids and azathioprine. In secondary sclerosing cholangitis, addressing the underlying cause, such as relieving obstruction, treating infection, or managing ischemic injury, is central to preventing further deterioration.
Antibiotics and Management of Cholangitis: Acute bacterial cholangitis requires prompt broad-spectrum antibiotic therapy and supportive care, often with hospital admission. Recurrent or refractory episodes may necessitate endoscopic or radiologic interventions to improve bile drainage, along with evaluation for strictures and stones.
Liver Transplantation: Liver transplantation is the only treatment known to restore normal liver function in advanced PSC. It is considered for people with decompensated cirrhosis, intractable pruritus, recurrent uncontrolled cholangitis, or selected early cholangiocarcinoma under specialized protocols. Outcomes of transplantation for PSC are generally favorable, although PSC can recur in the graft in a subset of recipients, and colon cancer risk in those with coexisting inflammatory bowel disease persists after transplant.

Outlook and Prognosis

What is the long-term outlook for people with sclerosing cholangitis?

The course of PSC is variable. Some individuals remain stable for many years with mild biochemical abnormalities, whereas others progress more quickly to advanced liver disease or develop malignancy.

Disease Progression: On average, many cohorts report progression over years to decades, but individual trajectories differ markedly. Factors associated with poorer outcomes include advanced age at diagnosis, high baseline bilirubin, certain imaging patterns, and early development of complications such as portal hypertension or dominant strictures.
Impact of Associated Inflammatory Bowel Disease: In those with PSC–IBD, prognosis reflects both liver disease and colonic involvement. Enhanced cancer surveillance and careful medical management of colitis are essential to reducing colorectal cancer risk and preserving quality of life.
Cancer Risk and Surveillance: The elevated risk of cholangiocarcinoma, gallbladder carcinoma, and colorectal cancer in PSC motivates structured surveillance strategies. These may include periodic imaging of the hepatobiliary system, gallbladder evaluation, and more frequent colonoscopy in individuals with coexisting inflammatory bowel disease. Early detection can improve treatment options, although screening strategies continue to evolve.
Transplant Outcomes: For those who undergo liver transplantation, survival rates are generally high compared with many other indications for transplant. People often experience substantial improvement in symptoms and functional status, although long-term monitoring for graft health, recurrent disease, and malignancy remains necessary.

Living With Sclerosing Cholangitis

How can someone live as well as possible with sclerosing cholangitis day to day?

Living with PSC or secondary sclerosing cholangitis involves partnering with a hepatology team, paying attention to symptoms, and implementing proactive strategies to maintain health and function.

Understanding Individual Disease Profile: Knowing whether the disease is early or advanced, whether inflammatory bowel disease is present, and what complications have occurred helps individuals understand their own risk landscape. Clear communication with clinicians about prognosis and monitoring plans can reduce uncertainty and support informed decisions.
Medication and Follow-Up Adherence: Taking prescribed medications consistently, attending scheduled imaging and endoscopic surveillance, and completing recommended laboratory testing are critical to detecting changes early. Bringing questions and symptom logs to visits helps focus discussions on what matters most in daily life.
Managing Pruritus and Fatigue: Itching and fatigue can significantly erode quality of life. Working closely with clinicians to adjust treatments, address sleep disruption, and evaluate for contributing factors such as anemia, malnutrition, thyroid dysfunction, or poorly controlled inflammatory bowel disease can make these symptoms more manageable.
Nutrition, Bone Health, and Activity: Maintaining a nutrient-dense diet, including adequate protein and calcium, supports liver health and muscle mass. Supplementation of fat-soluble vitamins is often needed. Weight-bearing and aerobic activity, tailored to the individual’s condition, can preserve strength, bone density, and mood.
Psychosocial Support: Chronic liver disease and the prospect of transplantation or cancer surveillance can be emotionally challenging. Counseling, peer support groups, and connection with others living with PSC or inflammatory bowel disease can provide validation, coping strategies, and practical advice.
Coordination of Multidisciplinary Care: Because PSC often intersects with gastroenterology, transplant hepatology, colorectal surgery, oncology, and primary care, coordinated care is essential. Clear documentation, shared treatment plans, and patient-held summaries can help align recommendations across specialties.

Seeking Care

When should someone with suspected or known sclerosing cholangitis see a healthcare provider?

Timely evaluation can reduce the risk of severe infection, acute decompensation, and missed malignancy.

New or Unexplained Liver Test Abnormalities: Persistent elevation of cholestatic liver enzymes, particularly alkaline phosphatase, warrants hepatology or gastroenterology evaluation, especially in individuals with inflammatory bowel disease or prior biliary interventions.
Symptoms Suggestive of Cholangitis or Obstruction: Sudden onset of fever, chills, right upper quadrant pain, and jaundice require urgent medical attention, often in an emergency setting. These features may indicate bacterial cholangitis or high-grade biliary obstruction and can rapidly become life-threatening without prompt treatment.
Progressive Jaundice, Pruritus, or Fatigue: Gradually worsening jaundice, itching that interferes with sleep or daily function, or a marked decline in energy should prompt reassessment of disease status and consideration of additional interventions or transplant evaluation.
Signs of Decompensated Cirrhosis: New ascites, lower extremity edema, confusion, easy bruising, gastrointestinal bleeding, or unintentional weight loss indicate possible decompensation and require urgent evaluation by a liver specialist.
Changes in Bowel Habits or Colorectal Symptoms: In people with PSC and inflammatory bowel disease, new or worsening rectal bleeding, altered stool frequency, or abdominal pain should be reported promptly, as they may signal active colitis, dysplasia, or colorectal cancer.
Routine Surveillance and Pre-Transplant Assessment: Even when symptoms are stable, regular follow-up to review imaging, laboratory data, endoscopic findings, and evolving evidence-based recommendations is essential. Early referral for transplant evaluation, before severe decompensation occurs, improves access to transplantation and post-transplant outcomes.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.